by Viviane Yang
Ahead of this year’s World Rare Disease Day, on February 28, JD Health announced its strategy to create an ecosystem to provide comprehensive services to people with rare diseases in China, helping them better access medical treatments, medications, health care management and financial support.
The approach is an elevation of JD Health’s Rare Disease Care Project that was launched last February. It is estimated that the project has provided medicines and medical support to more than 24,000 rare disease patients over the past 12 months.
JD Health Comprehensive Service Launch Ceremony for Rare Disease Patients
JD Pharmacy, the drug retail channel of JD Health, carries nearly 70% of approved rare disease drugs in China, making it the most comprehensive online retailer in this regard, according to the announcement. JD Health at the launch ceremony held in Beijing on February 27. .
The company has actively promoted the supply of rare disease drugs through close cooperation with domestic and foreign pharmaceutical companies. For example, last year JD Pharmacy became the first online distributor of Mayzent® (siponimod) from Novartis, an innovative multiple sclerosis (MS) drug, and FIRAZYR from Takeda, a newly imported injection for acute attacks of hereditary angioedema (HAE).
JD has also developed an exclusive integrated cold chain delivery service for rare disease drugs, which will be shipped from JD’s warehouse to patients’ doorsteps. By the end of December 2021, JD’s self-driving service covered more than 200 cities across China.
Meanwhile, a Patient Recruitment Center has been established at JD Pharmacy to connect patients to clinical trials and support the acceleration of new drug development. Patients can also submit their drug requests to a wishlist on JD Health that helps guide the company as it explores deeper cooperation with pharmaceutical companies to advance the market approval process.
A round table on the role of companies in the treatment of rare diseases with partners from pharmaceutical laboratories
On the life and financial support side, JD Health has provided fundraising, healthcare consultation, patient activities and knowledge sharing events with the Illness Challenge Foundation and other organizations in patients with rare diseases. So far, four groups of patients with different types of rare diseases, including hereditary epidermolysis bullosa, neuromyelitis optica, amyotrophic lateral sclerosis and idiopathic pulmonary hypertension, have regularly benefited from these services.
In an effort to expedite diagnosis, JD Health is working closely with pharmaceutical companies, foundations and other partners to explore new services such as inviting renowned physicians for telemedicine consultations, offering e-health courses on rare diseases, the provision of genetic testing and the creation of an e-learning section. to doctors in the field to help them in the diagnosis, treatment and rehabilitation of rare diseases.
“Rare diseases are not just a medical issue but more of a social issue,” said Enlin Jin, CEO of JD Health at the ceremony. “We have joined with many partners to continuously explore multiparty co-payment and public welfare models, and we hope that these advancements and initiatives will realize our original intent, which is to create tangible value for the courses in rare disease prevention and treatment.”
Jin said that JD Health’s “medical treatment + drug + service + payment” ecosystem for rare diseases will continue to be improved to serve patients and generate more public awareness and support.